

## Special Issue

# Resistance of Hematological Malignancies to CAR T Cell Therapy

### Message from the Guest Editor

Remarkable clinical responses have been observed in patients with hematological malignancies such as non-Hodgkin's lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma (MM) using modern immune-based approaches such as CD19CAR redirected adoptive T cell therapy (CAR T cell). Although very effective, innovative strategies are needed to improve CD19CAR T cell therapy, both in responding patients and in instances where tumors may have varying degrees of preexisting or acquired resistance to T cell-delivered apoptotic death signals. Understanding these mechanisms and obtaining strategies to render tumor cells more receptive to T cell killing could result in better response rates, reducing the intensity of the conditioning regimen or even the number of infused CAR T cells needed. This Special Issue focuses on the inherent or acquired resistance mechanisms of tumor cells which render them unresponsive to tumor-specific and highly effective CAR T cells and the design of novel strategies to render tumors sensitive to apoptotic death signals delivered by CAR T cells, thus creating a proapoptotic tumor microenvironment (immune-sensitization).

### Guest Editor

Dr. Ali R. Jazirehi

Department of Life Sciences, Los Angeles City College, Los Angeles, CA, USA

### Deadline for manuscript submissions

closed (30 September 2024)



## Cells

an Open Access Journal  
by MDPI

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/187326](https://mdpi.com/si/187326)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).